The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Cholesterol turnover

hdl / LDL-cholesterol turnover

State-of-the-art technique to investigate and quantify the effects of your compound on HDL-c / LDL-c metabolism as well as HDL/LDL-derived cholesterol fecal excretion.

key benefits

  • Directly detect a beneficial effects of your compound on HDL/LDL-cholesterol metabolism and HDL/LDL-derived cholesterol fecal excretion.
  • Direct mechanisms targeted by your compound: how your compound modulates HDL/LDL-cholesterol levels.
  • Essential and robust data to demonstrate that your compound promotes HDL/LDL-derived cholesterol fecal excretion and has therefore the potential to prevent atherosclerosis.

Description and parameters

HDL/LDL-cholesterol turnover using radioactive labeled tracers is a direct approach to evaluate drugs affecting HDL/LDL metabolism and reverse cholesterol transport.

Species

  • Hamster
  • Mouse

Reference compounds:

  • Torcetrapib, Anacetrapib (CETP inhibitor)
  • LXR agonist
  • Berberine

Parameters evaluated

  • Plasma total cholesterol, HDL/LDL-cholesterol and HDL/LDL-c/TC ratio
  • HDL/LDL-CE kinetic parameters: catabolism (fractional catabolic rate (FCR)) and production (absolute production rate (APR))
  • HDL/LDL-derived cholesterol fecal excretion: ³H-tracer recovered in fecal free sterols and bile acids

Add-on studies

Fact sheet

HDL LDL cholesterol kinetics

REFERENCES

Briand F. et al, Atherosclerosis, 2014, 233:359-362.
Briand F. et al, Arterioscler Thromb Vasc Biol. 2013,  33(1):13-23.
Castro-Perez J. et al, J Lipid Res, 2011, 52(11):1965-73.
Briand F. et al, J Lipid Res. 2010, 51(4):763-70.